TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 9,925,206 protecting the composition and methods of use of its lead anti-bacterial drug candidate, AB569.

TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that a Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products (DCRP) will take place on April 18, 2018 to review and confirm the key components of a planned IND application for Metablok (LSALT peptide) as a treatment to prevent acute kidney injury.

TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB:ACHFF), announced today it has closed the non-brokered private placement the Company disclosed in a press release January 26, 2018 (The “Offering”).